Sunday 18 October 2026
Export PALI’s income statement to Excel — free account
Palisade Bio, Inc.
PALI Healthcare Biotechnology
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.41
0.13
−8.44%
Follow PALI
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 6 | 4 | 1 | 3 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — | — |
Altman Z-Score |
(12.57) | (21.51) | (40.56) | (49.80) | (43.69) | — | — | (13.36) | — | — |
P/S ratio |
2,238.89 | 70.27 | 10.73 | 144.64 | 1,085.33 | — | — | 15.41 | — | — |
Altman Z″-Score (non-manufacturers) |
(28.98) | (48.61) | (89.30) | (110.62) | (110.50) | — | — | (25.09) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — | — |
Beneish M-Score |
(2.88) | 10.17 | (0.66) | (7.05) | — | — | — | — | — | — |
P/Operating CF |
(8.89) | (7.99) | (1.68) | (1.09) | (9.47) | — | — | (1.44) | — | — |
P/B ratio |
3.20 | 2.15 | 0.46 | 0.43 | 0.00 | — | — | 0.35 | — | — |
Price to Tangible BV |
3.51 | 2.40 | 0.53 | 0.50 | 0.00 | — | — | 0.36 | — | — |
EV/Sales |
1,378.22 | 44.89 | 8.00 | (175.75) | 1,117.04 | — | — | (31.89) | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.32 | 0.00 | — | — | 0.63 | — | — |
EV/Operating CF |
(1.43) | (0.87) | (0.27) | 0.37 | (3.16) | — | — | 0.74 | — | — |
EV/FCF |
(1.42) | (0.87) | (0.27) | 0.37 | (3.16) | — | — | 0.74 | — | — |
Quick Ratio |
2.76 | 7.95 | 5.85 | 4.19 | 0.10 | 4.20 | 4.11 | 4.81 | 3.03 | 28.77 |
Current Ratio |
2.85 | 8.22 | 6.19 | 4.61 | 0.11 | 4.61 | 4.89 | 5.15 | 3.24 | 28.95 |
Net Debt/EBITDA |
0.83 | 0.90 | 0.72 | 0.58 | (0.05) | 0.25 | 0.78 | 0.94 | 0.66 | 7.37 |
Debt/Assets |
16.39% | 0.00% | 0.00% | 2.75% | 37.79% | 0.70% | 0.56% | 1.12% | 0.73% | 0.29% |
Debt/Equity |
0.33 | 0.00 | 0.00 | 0.04 | (0.16) | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Asset Turnover |
0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
Operating CF/Net income |
0.74 | 0.86 | 1.56 | 0.87 | 0.46 | 0.56 | 0.94 | 0.90 | 0.84 | 0.65 |
Capex/Depreciation |
(0.14) | (0.03) | (0.01) | 0.00 | (2.00) | 0.00 | (3.33) | (1.00) | 0.00 | 0.00 |
Interest Coverage |
(18.08) | (83.64) | (1,072.66) | (969.85) | (39.56) | (17.45) | (1,209.31) | (871.33) | (1,238.25) | (1,805.60) |
| (258.77%) | (158.04%) | (67.72%) | (149.62%) | 179.86% | 576.17% | (143.75%) | (103.55%) | (153.59%) | (24.52%) | |
| (112.24%) | (85.87%) | (45.66%) | (117.07%) | (214.98%) | (342.75%) | (100.87%) | (82.62%) | (115.82%) | (23.11%) | |
ROIC |
0.00% | 0.00% | (1,966.55%) | (2,809.80%) | 0.00% | 0.00% | (5,340.01%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(152.26%) | (141.04%) | (88.77%) | (187.13%) | 143.74% | (295.31%) | (121.56%) | (114.55%) | (198.84%) | (12.95%) |
Average Days of Receivables |
1,432.96 | 521.67 | 502.58 | 500.10 | 1,595.19 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
81,209.26% | 3,113.88% | 1,523.15% | 26,373.38% | 22,955.56% | 0.00% | 0.00% | 2,757.20% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
46,279.01% | 2,104.23% | 1,753.58% | 29,776.62% | 45,911.11% | 0.00% | 0.00% | 2,480.80% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.04 | 0.06 | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
21,268.52% | 680.77% | 243.88% | 5,719.48% | 14,918.52% | 0.00% | 0.00% | 249.60% | 0.00% | 0.00% |
Graham Net Nets |
0.27 | 0.39 | 1.75 | 1.88 | (0.63) | — | — | 2.67 | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 25,311.88 | — | — | 0.00 | — | — |
Earnings Yield |
(64.68%) | (63.01%) | (103.15%) | (382.05%) | (160.26%) | — | — | (311.91%) | — | — |
Free Cash Flow Yield |
(43.33%) | (73.50%) | (276.18%) | (326.32%) | (32.59%) | — | — | (280.98%) | — | — |
Revenue per Share |
162.00 | 2,600.00 | 2,600.00 | 30.80 | 3.65 | 0.00 | 0.00 | 0.55 | 0.00 | 0.00 |
Operating CF per Share |
(156,161.00) | (134,162.00) | (76,924.00) | (14,511.40) | (1,288.65) | (1,191.37) | (227.60) | (24.41) | (8.61) | (0.19) |
Capex per Share |
(981.00) | (114.00) | (17.00) | 0.00 | (1.62) | 0.00 | (0.17) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(157,142.00) | (134,276.00) | (76,941.00) | (14,511.40) | (1,290.27) | (1,191.37) | (227.77) | (24.42) | (8.61) | (0.19) |
Cash per Share |
201,950.00 | 116,749.00 | 57,871.00 | 10,229.80 | 192.70 | 846.37 | 210.95 | 27.26 | 6.94 | 2.40 |
Shareholders Equity per Share |
113,308.00 | 85,151.00 | 60,496.00 | 10,252.00 | (1,918.65) | 593.95 | 212.59 | 24.81 | 5.29 | 2.32 |
Interest Debt per Share |
0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
113,308.00 | 85,151.00 | 60,496.00 | 10,252.00 | (1,918.65) | 593.95 | 212.59 | 24.81 | 5.29 | 2.32 |
Free Cash Flow |
(15.71) | (13.43) | (7.69) | (7.26) | (4.77) | (14.77) | (13.37) | (11.14) | (12.19) | (10.85) |
Working Capital |
13.57 | 10.93 | 5.46 | 4.42 | (7.19) | 9.01 | 11.72 | 10.74 | 7.26 | 129.59 |
Capital Expenditures |
(0.10) | (0.01) | 0.00 | — | (0.01) | — | (0.01) | 0.00 | — | — |
Net Current Asset Value |
9.63 | 7.08 | 4.87 | 4.19 | (9.22) | 6.36 | 11.45 | 10.59 | 7.11 | 129.26 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.31 | 0.00 | — | — | 0.63 | — | — |
Capex to Sales |
6.06 | 0.04 | 0.01 | 0.00 | 0.44 | — | 0.00 | 0.02 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.54 | 2.02 | 2.06 | 3.51 | 0.60 | 0.67 | 0.30 | 0.40 | 1.00 | 0.00 |
Cash ROIC |
(44.60%) | (66.51%) | (65.00%) | (69.62%) | 91.02% | (82.31%) | (53.59%) | (46.59%) | (70.11%) | (4.12%) |
Accounts Receivable Turnover |
0.32 | 1.19 | 0.71 | 0.08 | 0.34 | 0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.05 | 0.22 | 0.36 | 0.19 | 0.04 | 0.10 | 0.79 | — | — | — |
Average Payables |
1.90 | 1.61 | 0.85 | 0.83 | 1.68 | 1.93 | 1.54 | 1.23 | 0.90 | 0.94 |
Average Assets |
18.78 | 18.24 | 10.78 | 7.13 | 4.80 | 7.77 | 14.14 | 14.91 | 12.47 | 72.61 |
Average Common Equity |
8.14 | 9.91 | 7.27 | 5.58 | (5.74) | (4.62) | 9.92 | 11.89 | 9.40 | 68.43 |
Columns are period end dates